Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report.

Rundi Qi, Hailei Liu, Xin Li, Minglong Chen

Registry-linked trialAbstract readCase Reports

In one paragraph

Article in Current cardiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07388420 (Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07388420 narecruitingnot on this mapstarted 2026, after this paper: background citation

Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis: A Pilot Randomised Controlled Trial

TypeinterventionalSponsorGeneral Hospital of Shenyang Military RegionRan2026 to 2026Enrolled40ConditionsHypertriglyceridemia Induced Acute PancreatitisArmsEvolocumab 140 MG/ML [Repatha], Conventional lipid-lowering therapy

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rundi QiDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Hailei LiuDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Xin LiDepartment of Cardiology, Nanjing BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Minglong ChenDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionManaging hypertriglyceridemia-induced acute pancreatitis (HTG-AP) can be challenging, particularly due to the need for rapid triglyceride reduction to below 500mg/dL (5.645 mmol/L). CASE REPORT: This is a case describing a 39-year-old female patient who presented to the Emergency Department with acute abdominal pain resulting from severe HTG-AP. However, under conventional therapy with oral lipid-lowering drugs, the triglyceride levels remained uncontrolled. Oral moderate-intensity statins could not only reduce low-density lipoprotein cholesterol (LDLc) by 25%-50%. However, increasing the dose could not further reduce blood lipids while increasing the risk of liver damage. After the administration of proprotein convertase subtilisin/ kexin type 9 inhibitor (PCSK9i), the triglyceride levels were well controlled with no additional side effects, and the symptoms of the patients were completely relieved.

conclusionIn cases of unsatisfactory lipid control under conventional therapy, PCSK9i may offer a viable option for managing HTG-AP.

Indexed as

HypertriglyceridemiaPancreatitisPCSK9 InhibitorsAcute DiseaseAdultFemaleHumansProprotein Convertase 9Treatment OutcomeTriglyceridesPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Triglyceridesacute abdominal pain.acute pancreatitisHypertriglyceridemialow-density lipoprotein cholesterolproprotein convertase subtilisin/kexin type 9 inhibitortriglyceride reduction

Identifiers

PMID39773061

DOI10.2174/011573403X343784241115055037

PMCPMC12172237

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

NCT07388420ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.